MMulti-Immune HR
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 50 patients (estimated)
- Sponsors
- University of Arkansas for Medical Sciences (UAMS)
- Collaborators
- Johnson & Johnson
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), GPRC5D, Minimal Residual Disease (MRD)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2134
- NCT Identifier
- NCT07029776
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.